FEELM
1.7.2022 10:09:09 CEST | Business Wire | Press release
Industry and Information Technology Bureau of Shenzhen Municipality announced the list of the second batch of industrial design development support program in 2022. SMOORE, along with Shenzhen Skyworth, DJI and other technology companies were shortlisted.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220701005128/en/
The industrial design development support program supports the recognized industrial design centers or industrial design team of enterprises with strong innovation capabilities, design distinctiveness, and key competencies.
Meanwhile, the Industry and Information Technology Bureau of Shenzhen Municipality requests the shortlisted parties to lead and support both the advanced manufacturing and prevailing traditional industries with industrial design capability. Ultimately, enterprises shall achieve improvements in four aspects: external appearance, friendly user experience, branding and quality assurance, further to convert the improvements to deployment.
The public information of the shortlist announcement discloses that in-house industrial design team of FEELM, the flagship atomization tech brand of SMOORE wins the recognition out of its "innovative design and achievement transformation of closed-pod electronic atomizer based on leadless ceramic heating technology."
FEELM industrial design team has created a number of design works that combine technological attributes, practicality and consumer caring, empowering FEELM’s electronic atomization solution to connect consumer experience with advanced smart manufacturing.
From 2020 to 2022, FEELM industrial design team has won 8 prestige International design awards including the Red Dot Award, the iF Design Award, the German National Design Award and the MUSE Design Award.
In 2022, 4 product designs of FEELM won Red Dot Product Design Award, known as the "Oscar" of global industrial design at once. Among it, the vape design inspired from the design ingenuity of lipstick, which the nozzle can be twisted to hide the mouthpiece from getting on dusts receives positive feedbacks due to the clean and hygiene product experience it brings.
Another awarded product design is FEELM eco-friendly disposable e-cigarette. Its external structure is composed of recyclable and reusable aluminum foil. It looks like a paper foil pouch and itself serves as a packaging bag, hence to reduce the excessive consumption of packaging materials.
Meanwhile, one of the key competencies of FEELM – the automation capacity can ensure mass production of innovative, design-led products, to be further launched in global consumer market through FEELM’s global business partners.
As a global leading vaping tech brand, the industrial design concepts presented by FEELM is not only own manifestation of social responsibility, but also a shorthand to show brand innovation capabilities, R&D investment, talent construction, and business performance.
The head of FEELM Industrial design team, Totom Lu says, "FEELM design devotes to helping clients in improving user experience from the perspective of vaping tech brand, keep pushing it to the new heights. I think the future direction of design of closed-pod vaping solution should lean on 3 dimensions: product experience; emotional experience, which is to identify problems before users notice them and sustainable experience, to focus on product sustainability."
About FEELM:
As a flagship tech brand belonging to SMOORE, FEELM is the world’s leading closed vape system solution provider. Based on the world's leading Ceramic Coil Heating Technology, FEELM combines authentic Flavor Reproduction Technology with innovative electronics technology, bringing ultimate sensation and premium vaping experience.
About SMOORE:
SMOORE is a global leader in offering vaping technology solutions, including manufacturing vaping devices, and vaping components for HNB products on an ODM basis, with advanced R&D technology, strong manufacturing capacity, wide-spectrum product portfolio and diverse customer base.
According to Frost & Sullivan, SMOORE is the world’s largest vaping device manufacturer in terms of revenue, accounting for 22.8% of the total global market share, in 2021. Its global market share is bigger than the sum of those listed from No.2 to No.5.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220701005128/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom